非阻塞性肥厚性心肌病的病理生理学和治疗需求。

IF 11.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Heart failure Pub Date : 2025-09-24 DOI:10.1016/j.jchf.2025.102658

Milind Y. Desai MD, MBA , Niccolo Maurizi MD , Elena Biagini MD , Philippe Charron MD, PhD , Fabio Fernandes MD , Esther González-López MD , Paul L. van Haelst MD, PhD , Kristina Hermann Haugaa MD , Christopher M. Kramer MD , Benjamin Meder MD , Michelle Michels MD, PhD , Anjali Owens MD , Shinsuke Yuasa MD , Perry Elliott MBBS

{"title":"非阻塞性肥厚性心肌病的病理生理学和治疗需求。","authors":"Milind Y. Desai MD, MBA , Niccolo Maurizi MD , Elena Biagini MD , Philippe Charron MD, PhD , Fabio Fernandes MD , Esther González-López MD , Paul L. van Haelst MD, PhD , Kristina Hermann Haugaa MD , Christopher M. Kramer MD , Benjamin Meder MD , Michelle Michels MD, PhD , Anjali Owens MD , Shinsuke Yuasa MD , Perry Elliott MBBS","doi":"10.1016/j.jchf.2025.102658","DOIUrl":null,"url":null,"abstract":"<div><div>Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitations, ventricular tachyarrhythmias, progression to heart failure, and atrial fibrillation. No approved pharmaceutical therapies target the pathophysiology of nonobstructive HCM, although several clinical trials are underway. This narrative review provides a comprehensive overview of nonobstructive HCM, focusing on epidemiology, natural history, genetics, pathophysiology, clinical manifestations, diagnosis, burden of disease, and current treatments and ongoing clinical trials.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 11","pages":"Article 102658"},"PeriodicalIF":11.8000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy\",\"authors\":\"Milind Y. Desai MD, MBA , Niccolo Maurizi MD , Elena Biagini MD , Philippe Charron MD, PhD , Fabio Fernandes MD , Esther González-López MD , Paul L. van Haelst MD, PhD , Kristina Hermann Haugaa MD , Christopher M. Kramer MD , Benjamin Meder MD , Michelle Michels MD, PhD , Anjali Owens MD , Shinsuke Yuasa MD , Perry Elliott MBBS\",\"doi\":\"10.1016/j.jchf.2025.102658\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitations, ventricular tachyarrhythmias, progression to heart failure, and atrial fibrillation. No approved pharmaceutical therapies target the pathophysiology of nonobstructive HCM, although several clinical trials are underway. This narrative review provides a comprehensive overview of nonobstructive HCM, focusing on epidemiology, natural history, genetics, pathophysiology, clinical manifestations, diagnosis, burden of disease, and current treatments and ongoing clinical trials.</div></div>\",\"PeriodicalId\":14687,\"journal\":{\"name\":\"JACC. Heart failure\",\"volume\":\"13 11\",\"pages\":\"Article 102658\"},\"PeriodicalIF\":11.8000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC. Heart failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213177925005864\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Heart failure","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213177925005864","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

肥厚性心肌病（HCM）影响全世界的个体，估计患病率超过1 / 500。非阻塞性HCM约占病例的30% - 70%，异质性极大，并与显著程度的发病率相关，包括日常生活受限、室性心动过速、心力衰竭和心房颤动。虽然一些临床试验正在进行中，但目前还没有批准的药物治疗针对非阻塞性HCM的病理生理。这篇叙述性综述提供了非阻塞性HCM的全面概述，重点是流行病学、自然史、遗传学、病理生理学、临床表现、诊断、疾病负担、当前治疗和正在进行的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitations, ventricular tachyarrhythmias, progression to heart failure, and atrial fibrillation. No approved pharmaceutical therapies target the pathophysiology of nonobstructive HCM, although several clinical trials are underway. This narrative review provides a comprehensive overview of nonobstructive HCM, focusing on epidemiology, natural history, genetics, pathophysiology, clinical manifestations, diagnosis, burden of disease, and current treatments and ongoing clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JACC. Heart failure CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

21.20

自引率

2.30%

发文量

164

期刊介绍： JACC: Heart Failure publishes crucial findings on the pathophysiology, diagnosis, treatment, and care of heart failure patients. The goal is to enhance understanding through timely scientific communication on disease, clinical trials, outcomes, and therapeutic advances. The Journal fosters interdisciplinary connections with neuroscience, pulmonary medicine, nephrology, electrophysiology, and surgery related to heart failure. It also covers articles on pharmacogenetics, biomarkers, and metabolomics.